期刊
MARINE DRUGS
卷 19, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/md19020079
关键词
Streptoglutarimide H; lung cancer cells; antiproliferative activity; cell cycle block; glycolysis; USP28; c-Myc
资金
- National Key R&D Program of China [81773587]
- [2018YFC0310600]
Streptoglutarimide H (SGH) was identified as a new glutarimide from marine-derived actinomycete with in vitro antiglioma activity. SGH was found to significantly inhibit lung cancer cell proliferation by downregulating cell cycle-related proteins, glycolytic enzymes, and important cancer transcription factors. The potent anticancer activity and multiple mechanisms suggest SGH as a novel antitumor compound against lung cancer cells.
In 2019, streptoglutarimide H (SGH) was characterized as a new glutarimide from the secondary metabolites produced by a marine-derived actinomycete Streptomyces sp. ZZ741 and shown to have in vitro antiglioma activity. However, the antiproliferative activity and potential mechanism of SGH against lung cancer cells have not yet been characterized. This study demonstrated that SGH significantly inhibited the proliferation of different lung cancer cells. In terms of mechanism of action, SGH downregulated cell cycle- and nucleotide synthesis-related proteins to block cell cycle at G0/G1 phase, reduced the expression levels of glycolytic metabolic enzymes to inhibit glycolysis, and downregulated the important cancer transcription factor c-Myc and the therapeutic target deubiquitinase USP28. Potent anticancer activity and multiple mechanisms indicated SGH to be a novel antitumor compound against lung cancer cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据